Expanding possibilities for next-generation vaccines and biologics
Thank you for your interest in investing in Ziccum. Our unique ambient drying technology, LaminarPace, formulates next-generation vaccines and biologics as particle-engineered powders that are thermostable and also highly suited for novel administration routes.
Meet our CEO Ann Gidner
In a global career spanning 25 years our CEO Ann Gidner has driven growth and built powerful networks throughout the pharmaceutical and life science industries. Ann’s expertise combines extensive experience in implementing new business models with a passion for creating new partnerships and achieving steep, sustainable growth.
Explore our Business Model
Ziccum offers licenses and tech transfers to vaccine and biotherapeutics companies based on our patent portfolio and continuous technology development. Our overall objective is to enter into one or more license agreements with one or more major pharmaceutical companies.
Sustainability and next-generation vaccines
Find out how sustainability is at the heart of Ziccum’s strategic, business and operational focus. We believe that ambient drying and next-generation thermostable vaccines can reduce the carbon footprint of vaccine production and play a valuable role in key United Nations Sustainable Development Goals.
Explore Ziccum and sustainability
Contact us about your investment
Please do not hesitate to contact our CFO Frida Hjelmberg directly for further information.
Frida Hjelmberg
CFO
Mobile: +46 793 41 55 31
e-mail: hjelmberg@ziccum.com